Day One

Kick off the summit by getting to know the people at your table. Each attendee will have the opportunity to briefly introduce themselves, share their role and current focus in amylin R&D, and identify the challenges they are most interested in discussing – making it easier to spot relevant peers, start conversations early and build stronger connections throughout the meeting.

• Trace the evolution of amylin from its discovery within pancreatic amyloid deposits to recognition as a co-secreted metabolic hormone, revealing how changing biological understanding transformed an apparent marker of disease into a viable therapeutic target 
• Review the foundational pharmacology that established amylin’s roles in satiety, gastric emptying, glucagon regulation and nutrient control, highlighting the experiments and translational decisions that enabled development of the first amylinmimetic medicines
• Reflect on the scientific and development lessons from Amylin Pharmaceuticals, including receptor uncertainty, peptide stability and formulation challenges, to identify what today’s developers should retain, or reconsider, when engineering the next generation of amylin therapeutics

• Review how early fibrillation challenges were addressed through sequence modification and alternative peptide backbones
• Examine the remaining trade-offs between stability, aggregation, receptor pharmacology, concentration, formulation and manufacturability
• Separate developability challenges of therapeutic analogues from the biological significance of endogenous amylin aggregation in diabetes and other diseases

• Examine the Phase II dose-response findings for once-weekly zenagamtide, including HbA1c reductions of up to 1.71 percentage points and body-weight loss of up to 14.6% at 36 weeks, to assess the clinical potential of combining GLP-1 and amylin receptor agonism within a single molecule
• Explore how dose escalation, receptor balance and exposure influenced efficacy and gastrointestinal tolerability, enabling developers to refine therapeutic windows and make more informed dose-selection decisions for next-generation co-agonists
• Translate the findings into future development strategy, from identifying the patient populations most likely to benefit to determining how dual GLP-1/amylin assets can differentiate from established incretins as zenagamtide advances toward Phase III development

Session details to be confirmed.

• Explore how fully selective antibodies can distinguish between AMY1, AMY3 and calcitonin receptor activity, moving beyond broadly biased peptide agonists to identify which receptor profiles drive weight loss, tolerability and body-composition outcomes
• Examine how parallel interrogation of G-protein and β-arrestin signaling can connect cellular mechanism with in vivo performance, enabling more rational optimization of potency, signaling bias and receptor engagement rather than relying on clinical trialand-error
• Assess the potential of ultra-long-acting amylin antibodies to deliver infrequent dosing, sustained receptor coverage and improved treatment adherence, helping developers pursue durable efficacy while reducing adverse effects, treatment burden and weight cycling

• Expose how conventional cAMP assays generate composite signals from mixed populations of free calcitonin receptors and amylin receptor heterodimers, obscuring the true activity of individual ligands
• Introduce new assays capable of distinguishing AMY1, AMY2 and AMY3 heterodimers within mixed receptor populations, enabling direct pharmacological characterisation of each receptor subtype
• Examine how different ligands influence receptor-subunit association, dissociation and signalling dynamics, revealing functional differences between the three amylin receptor complexes
• Explore how receptor-specific pharmacology and signalling kinetics could ultimately be linked with clinical efficacy and tolerability to support rational ligand design

• Compare emerging efficacy, tolerability, titration and discontinuation patterns across selective amylin agonists, balanced agonists and amylin-containing combinations, distinguishing molecule-specific effects from potential class effects 
• Interrogate whether current clinical performance supports proposed hypotheses around receptor selectivity, exposure, signalling bias and dose escalation, identifying which mechanistic assumptions require revision 
• Translate clinical successes and disappointments back into preclinical decisionmaking, enabling earlier programs to update target product profiles, assays and candidate-selection criteria before entering costly trials

• Compare how developers are approaching patient selection, from GLP-1 non responders and intolerant patients to first-line treatment populations
• Debate which endpoints beyond headline weight loss will be most valuable, including body composition, metabolic outcomes, quality of life and weight maintenance
• Discuss when placebo remains appropriate versus when active GLP-1 comparators are needed to demonstrate meaningful differentiation
• Share how trial design should evolve across monotherapy, combination strategies and different intended product profiles

• Compare amylin and CGRP receptor architecture, shared RAMP biology, expression and challenges in assigning ligand selectivity
• Apply lessons from CGRP assay development, nomenclature and receptor characterisation to improve consistency in the amylin field
• Identify where decades of CGRP drug development can inform target validation, translational pharmacology and therapeutic differentiation